Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bladder Cancer
Clinical trial register · China

Bladder Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 18 Shanghai 13 Beijing 10 Changsha 8 Nanjing 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University8 Tianjin Medical University Second Hospital6 Qilu Hospital of Shandong University4 Zhujiang Hospital3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences3
Site location
Guangzhou18 Shanghai13 Beijing10 Changsha8 Nanjing8
All 37 locations
Target enrolment
to

Bladder Cancer trials in China

53 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
20
Guangzhou
2027-01-01
Not yet open
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2026-09-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Not yet open
Tianjin Medical University Second Hospital
Phase 2/3
114
Tianjin
2026-08-01
Not yet open
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
NCT07662863Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
DrugSacituzumab tirumotecan
Fudan University
Phase 2
75
Shanghai
2026-07-15
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
80
Guangzhou
2026-07-01
Not yet open
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
35
Nanjing
2026-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
NCT07888374Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer
Ruijin Hospital
Observational
477
Shanghai
2026-04-05
Recruiting
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
NCT07492628Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1
42
Shenzhen
2026-03-02
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
250
Beijing
2026-03-01
Recruiting
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
NCT07424560Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer
Zhilong Dong
Observational
400
Lanzhou
2026-02-25
Recruiting
Changhai Hospital
Phase 2
31
Shanghai
2025-12-08
Not yet open
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
NCT07261592Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy
DrugEntinostat
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
29
Nanjing
2025-12-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2025-10-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
210
Guangzhou, Wuhan, Changsha
2025-10
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
350
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Active, closed
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Changhai Hospital
Not applicable
180
Shanghai
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Observational
60
Tianjin
2025-09-01
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
Changsha
2025-08-20
Recruiting
Peking University First Hospital
Observational
400
Beijing
2025-05-27
Not yet open
Sun Yat-sen University
Phase 1/2
30
Guangzhou
2025-04-30
Recruiting
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
NCT07721935Urinary Stones, Prostate Cancer, Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou, Shantou, Ganzhou
2025-04-01
Recruiting
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
NCT06926374Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer
Chinese University of Hong Kong
Not applicable
90
Hong Kong
2025-03-25
Recruiting
RenJi Hospital
Not applicable
20
Shanghai
2025-02-08
Recruiting
Qilu Hospital of Shandong University
Observational
224
Jinan
2025-01-01
Recruiting
Qilu Hospital of Shandong University
Observational
254
Jinan
2025-01-01
Recruiting
Qilu Hospital of Shandong University
Observational
266
Jinan
2025-01-01
Recruiting
Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06851663Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer
Drugs[68Ga]Ga-NOTA-RT4·[18F]F-RESCA-RT4·[18F]F-RESCA-T4·[68Ga]Ga-NOTA-T4
RenJi Hospital
Phase 2/3
400
Shanghai
2024-12-23
Recruiting
Adaptive Radiotherapy for Genitourinary Cancers
NCT07324798Prostate Cancer (Post Prostatectomy), Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
60
Beijing
2024-12-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-12-01
Recruiting
Qilu Hospital of Shandong University
Observational
293
Binzhou, Dezhou, Jinan, Jining, Liaocheng, Linyi, Qingdao, Taian
2024-10-01
Recruiting
Zhujiang Hospital
Not applicable
126
Guangzhou
2024-09-10
Not yet open
Changhai Hospital
Observational
1,200
Shanghai
2024-07-01
Recruiting
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
NCT06341400Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Zhujiang Hospital
Phase 1/2
55
Guangzhou
2024-06-19
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
36
Guangzhou, Wuhan, Changsha
2024-05-15
Recruiting
Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer
NCT06775977Bladder Cancer, Staging, Contrast Enhanced Ultrasound
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
Mingzhao Xiao
Observational
1,000
Chongqing
2024-01-01
Recruiting
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Recruiting
First Affiliated Hospital of Chongqing Medical University
Observational
500
Chongqing
2023-08-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
Fudan University
Phase 2
30
Shanghai
2022-09-10
Recruiting
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05072600Bladder Cancer, Bladder Neoplasms, Bladder Tumors, Urinary Bladder Cancer
DrugPembrolizumab
Peking University First Hospital
Phase 2
54
Beijing
2021-12-07
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2021-07-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Guangzhou, Changsha, Nanjing, Nantong, Shanghai
2021-04-21
Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT04532606Benzodiazepines, Bladder Cancer, Delirium, Surgery
DrugsRemimazolam·Propofol
Peking University First Hospital
Phase 4
1,128
Beijing, Beijin, Guiyang, Nanjing, Shanghai
2021-02-05
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1,000
Guangzhou
2020-04-01
Recruiting
Zhujiang Hospital
Not applicable
96
Guangzhou
2018-05-02
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/bladder-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies listing the condition Bladder Cancer.

How many Bladder Cancer trials are recruiting in China?

39 of the 53 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 9 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bladder Cancer), 53 studies
PhaseStudiesRecruitingShare
Observational171532.1%
Not applicable111020.8%
Phase 28515.1%
Phase 1/2539.4%
Phase 1427.5%
Phase 3417.5%
Phase 2/3325.7%
Phase 4111.9%

Most active sponsors

Lead sponsors with the most studies (Bladder Cancer)
Lead sponsorStudiesRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University86
Tianjin Medical University Second Hospital64
Qilu Hospital of Shandong University44
Cancer Institute and Hospital, Chinese Academy of Medical Sciences32
Changhai Hospital32
Peking University First Hospital33
RenJi Hospital33
Zhujiang Hospital33
Fudan University20
Merck Sharp & Dohme LLC21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.